Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series-Reference-Cited by-同舟云学术

Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series

Published:2023-06 Issue:3 Volume:62 Page:103722
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Albanell-Fernández Marta,Monge-Escartín Inés,Carcelero-San Martín Esther,Riu Viladoms Gisela,Ruiz-Boy Sonia,Lozano Miquel,Soy Dolors,Moreno-Castaño Ana Belén,Diaz-Ricart Maribel,Cid Joan

Publisher

Elsevier BV

Subject

Hematology

Reference19 articles.

1. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura;Scully;N Engl J Med,2019

2. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura;Völker;Blood Adv,2020

3. Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: a single-center with homogeneous treatment experience;Jiménez;Transfusion,2022

4. TTP: the evolution of clinical practice;George;Blood,2021

5. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI);Cid;Transfus Apher Sci,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

2. Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura;Expert Review of Hematology;2024-05-20

3. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy;Blood;2024-05-02

4. Caplacizumab/corticosteroids/vincristine;Reactions Weekly;2023-12-02

5. Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura;Journal of Thrombosis and Haemostasis;2023-10